Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Change in Account Payables (2016 - 2025)

KalVista Pharmaceuticals' Change in Account Payables history spans 10 years, with the latest figure at -$1.4 million for Q2 2025.

  • For Q2 2025, Change in Account Payables fell 122.83% year-over-year to -$1.4 million; the TTM value through Apr 2025 reached $348000.0, down 91.94%, while the annual FY2025 figure was -$5.0 million, 215.07% down from the prior year.
  • Change in Account Payables for Q2 2025 was -$1.4 million at KalVista Pharmaceuticals, up from -$5.9 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $6.1 million in Q2 2024 and bottomed at -$5.9 million in Q4 2024.
  • The 3-year median for Change in Account Payables is $55000.0 (2023), against an average of -$204285.7.
  • The largest YoY upside for Change in Account Payables was 1290.74% in 2024 against a maximum downside of 10754.55% in 2024.
  • A 3-year view of Change in Account Payables shows it stood at $55000.0 in 2023, then plummeted by 10754.55% to -$5.9 million in 2024, then skyrocketed by 76.25% to -$1.4 million in 2025.
  • Per Business Quant, the three most recent readings for KALV's Change in Account Payables are -$1.4 million (Q2 2025), -$5.9 million (Q4 2024), and $1.5 million (Q3 2024).